When do co-infections matter?
File(s)When_do_co_infections_matter_.2.pdf (328.17 KB)
Published version
Author(s)
Mcardle, Andrew
Turkova, Anna
Cunnington, A
Type
Journal Article
Abstract
Purpose of review: Advances in diagnostic methods mean that co-infections are increasingly being detected in clinical practice, yet their significance is not always obvious. In parallel, basic science studies are increasingly investigating interactions between pathogens to try to explain real-life observations and elucidate biological mechanisms.
Recent findings: Co-infections may be insignificant, detrimental or even beneficial, and these outcomes can occur through multiple levels of interactions which include modulation of the host response, altering the performance of diagnostic tests and drug-drug interactions during treatment. The harmful effects of chronic co-infections such as tuberculosis or Hepatitis B and C in association with HIV are well established, and recent studies have focussed on strategies to mitigate these effects. However consequences of many acute co-infections are much less certain, and recent conflicting findings simply highlight many of the challenges of studying naturally acquired infections in humans.
Summary: Tackling these challenges, using animal models or careful prospective studies in humans may prove to be worthwhile. There are already tantalising examples where identification and treatment of relevant co-infections seems to hold promise for improved health outcomes.
Recent findings: Co-infections may be insignificant, detrimental or even beneficial, and these outcomes can occur through multiple levels of interactions which include modulation of the host response, altering the performance of diagnostic tests and drug-drug interactions during treatment. The harmful effects of chronic co-infections such as tuberculosis or Hepatitis B and C in association with HIV are well established, and recent studies have focussed on strategies to mitigate these effects. However consequences of many acute co-infections are much less certain, and recent conflicting findings simply highlight many of the challenges of studying naturally acquired infections in humans.
Summary: Tackling these challenges, using animal models or careful prospective studies in humans may prove to be worthwhile. There are already tantalising examples where identification and treatment of relevant co-infections seems to hold promise for improved health outcomes.
Date Issued
2018-06-01
Date Acceptance
2018-03-09
Citation
Current Opinion in Infectious Diseases, 2018, 31 (3), pp.209-215
ISSN
0951-7375
Publisher
Lippincott, Williams & Wilkins
Start Page
209
End Page
215
Journal / Book Title
Current Opinion in Infectious Diseases
Volume
31
Issue
3
Copyright Statement
© 2018 Wolters Kluwer Health, Inc. All rights reserved. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
http://creativecommons.org/licenses/by/4.0
http://creativecommons.org/licenses/by/4.0
Sponsor
Medical Research Council (MRC)
Grant Number
MR/L006529/1
Subjects
Science & Technology
Life Sciences & Biomedicine
Infectious Diseases
co-infection
diagnosis
interactions
pathogenesis
susceptibility
treatment
HEPATITIS-C VIRUS
HIV-INFECTED PATIENTS
ANTIRETROVIRAL THERAPY
SOUTH-AFRICA
INFLAMMATORY RESPONSE
LIVER-DISEASE
COHORT
TUBERCULOSIS
RISK
CHILDREN
1103 Clinical Sciences
1108 Medical Microbiology
0605 Microbiology
Microbiology
Publication Status
Published
Article Number
QCO310302